Directory · JP
Biotechnology Research in Japan
A register of firms and the professionals working at them in the Biotechnology Research sector based in Japan. Browse the public index, then filter or export on Kipplo.
Companies
256 on file
Carna Biosciences, Inc
Carna Biosciences, a biotechnology company focusing on kinases as the important targets for the development of drugs to treat a variety of diseases, including cancer, inflammation, and neurological disorders, offers a wide range of kinase protein products all developed and manufactured in-house and assay services with extensive kinase targets for your research and development. Our biochemical assay services are boast of delivering highly reproducible quality data by employing only our in-house kinases which have passed our stringent QC and conducting experiments under the thoroughly managed assay system by skilled hands. Our cell-based assays which investigate your compounds’ binding activities generate reliable data utilizing the well-established Promega’s NanoBRET™ technology. In addition to these kinase products and services, our rich experiences, deep knowledge, and know-how in drug discovery targeting kinases will give you unparalleled support which surely helps accelerate your drug discovery. If you are engaged in kinase inhibitor research and development, Carna Biosciences will be your best support partner.
51 to 200 staff
Thinkcyte
ThinkCyte’s mission is to provide scientists and biomedical professionals with a transformational single-cell technology that accelerates biological discoveries and enable the development of novel treatments and diagnostics through the integration of advanced hardware, machine learning, and biotechnology.
51 to 200 staff
Yokogawa Life Science
For more than 30 years, Yokogawa Life Science has developed and provided innovative instruments based on original and proprietary confocal microscopy technologies. Our products: High Content Imaging systems and Confocal scanners specialize in live-cell and 3D imaging, enabling visualization and image analysis of dynamic cellular phenomenon. We are dedicated to the development of novel products employing microscopy and/or image analysis technology for the advancement of cell biology research and drug discovery. Follow us on Twitter:@Yokogawa_LS
5001 to 10000 staff
Cardurion Pharmaceuticals
Cardurion Pharmaceuticals is a next generation cardiovascular company focused on the discovery and development of novel therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by an experienced team of CV experts and industry veterans, we are developing groundbreaking clinical programs in PDE9 and CaMKII inhibition. We take a strategic portfolio approach driven by in-house drug discovery and our office of strategy and have concluded foundational partnerships with key strategics and investors, including an up to $300 million dollar investment from Bain Capital to support current programs and pipeline growth. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at
11 to 50 staff
Nxera Pharma
Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
201 to 500 staff
Alnylam Pharmaceuticals
SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe,+31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."
1001 to 5000 staff
Goryo Chemical, Inc
GORYO Chemical, Inc. provides new fluorescent probes for cellular analysis, assay, and imaging. AcidiFluor™ ORANGE is a fluorescence imaging probe which enhances fluorescence dramatically in acidic environments. This probe can selectively stain acidic organelles such as lysosome, late endosomes and granules. Its has excellent selectivity enabling it to detect acidic environments. At pH 5.0, identical to the environment of acidic organelles, the fluorescence intensity is 50-fold or more compared to pH 7.4. AcidiFluor™ ORANGE shows excellent photostability to excitation light. CaSiR-1™ and CaSiR-1™ AM are near-infrared fluorescence calcium probes which have fluorescence maximum wavelength at 664 nm. Multicolor imaging is possible between CaSiR-1™ or CaSiR-1™ AM and fluorescent probes or fluorescent proteins which have fluorescent wavelength in visible range such as Hoechst, Fluorescein, Rhodamine, GFP, YFP and RFP etc. The near-infrared region has greater tissue penetration, less overlap with the spectrum of background autofluorescence and exhibits less phototoxicity to cells and tissue. GlycoYELLOW™-βGal is a specific fluorescent probe for detection of β-galactosidase. It can be used in fluorescent imaging and identification of cells and tissue transfected with lacZ. Because GlycoYELLOW™-βGal is almost non-fluorescent in the absence of β-galactosidase, this probe exhibits an excellent S/N ratio.
11 to 50 staff
Molcure Inc
MOLCURE was founded in 2013 with a mission to build the best platform for biologics discovery in the world. Today, its platform integrates AI with evolutionary molecular engineering, next-generation sequencing, laboratory automation technologies, and a proprietary database containing more than one billion molecular entries. These capabilities enable the delivery of diverse, high affinity, specific, and functional antibodies and peptides for researchers. MOLCURE is partnering with innovative companies to discover therapeutics with the potential to benefit patients around the world.
11 to 50 staff
Setsuro Tech Inc
Setsuro Tech Inc. is a biotech startup that originated from Tokushima University and was founded in 2017. The company's mission is to "create industries that solve your and the planet's problems by harnessing from the potential of living organisms". Our company provides innovative genome editing technology and contributes to the advancement of industry and human health and well-being. We use proprietary technologies to provide contract genome editing R&D services to researchers in academia and industry. Our goal is to provide genome-edited organisms broadly available to society and to advance the genome editing industry. The name of our service, PAGEs, stands for Platform App(lication) using Genome Editing by Setsuro Tech. We named it with the idea that "genome editing will add new pages to all industries worldwide and bring about a revolution in the genome editing industry". With PAGEs, Setsuro Tech's genome editing technology can be used to develop new traits in a wide range of species and produce useful and valuable substances. Regardless of the size of the company or the scope of the business or industry, Setsuro Tech's PAGEs are creating breakthroughs in current production systems and providing solutions to social and environmental problems.
11 to 50 staff
Cell Signaling Technology Cst
Founded by research scientists in Cell Signaling Technology (CST) is a private, family-owned company that prides itself on operating as a research institute developing quality products for other researchers. Active in the field of applied systems biology research, particularly as it relates to cancer, CST understands the importance of using antibodies. That's why all of our antibodies are painstakingly validated for multiple applications by our Ph.D. level scientists. And the same CST scientists who helped produce your antibody will also provide technical support, methods, and guidance needed to achieve the most reliable results. Check out our website! For Research Use Only. Not for Use in Diagnostic Procedures.
501 to 1000 staff
Gellycle
Gellycle - Japanese Biotech Company aiming to apply innovative hydrogel technology in the medical field. Tetra Gel, a groundbreaking biocompatible solution is uniquely formulated from branched polyethylene glycol (PEG) and water. This innovative gel offers precise control over “gelation time”, “degradation time”, “elasticity and elongation ratio”, “swelling property”, and “pore size”. This advanced formulation enables the precise production of porous structures and customizable tissue adhesiveness, meeting the highest demands of modern medical applications. Whether uniformly applied via spray or instantly activated upon contact with blood or bodily fluids, our Tetra Gel ensures optimized performance across a wide array of medical fields, revolutionizing the way we approach healthcare solutions. Tetra Gel is used in a wide range of applications including Cell Tissue Regeneration Materials (fat, nerves, tendons, bones), Drug Delivery Systems (DDS), Anti-Adhesion Agents, Ophthalmic Viscoelastic Device (OVD), Artificial Vitreous, Hemostatic Agents, Hydro Release, Iontophoresis, Wound Dressing, Gel Threads, and beyond. Gellycle has conducted numerous joint research and development projects with leading medical device manufacturers, pharmaceutical companies, and academic institutions both in Japan and globally. We take great pride in our technological superiority and reliability, which are the cornerstones of our reputation and success. If you are looking for innovative materials or cutting-edge technologies, we invite you to consult with us.
11 to 50 staff
Algal Bio
Our principal mission is to cultivate algae's potential based on our unique capabilities built upon our access to approximately algae strains. Our unique capabilities with proprietary breeding technology, strain screening capability and cultivation expertise will put us in a unique position unlocking algae's potential for a better future.
11 to 50 staff
Chiome Bioscience
Chiome Bioscience, Inc. is a biotechnology company established in 2005 that specializes in the R&D of antibody drug discovery and technology. One of our major businesses is the drug discovery business, and we are promoting R&D of antibody drug pipelines with the aim of licensing them to pharmaceutical companies. We also have another business, the drug discovery support business, where we develop partnerships and contract services with pharmaceuticals, diagnostics, biotechs, and academic institutions, utilizing our own antibody generation (ADLib® system) and optimization technologies, and protein expression technologies.
51 to 200 staff
Jsr Life Sciences
A business unit of JSR Corporation, JSR Life Science LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR LS provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR LS offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines and increase clinical success rates. JSR LS’s global network of affiliates includes Crown Bioscience and KBI Biopharma, Inc. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide.
1001 to 5000 staff
Kobe Biomedical Innovation Cluster
KOBE Biomedical Innovation Cluster (KBIC) is the largest biomedical cluster in Japan, and it offers a platform of networking for businesses and institutes in their pursuit of innovative collaboration. KBIC currently boasts a concentrated network of close to about 370 companies, universities, research institutes, and specialized hospitals, in addition to a growing network of international bio-cluster partners, who are all focused on the development of innovative medical technology and pioneering discoveries through collaboration. KBIC is also the home of the Foundation for Biomedical Research and Innovation at Kobe (FBRI), which vigorously pursues biomedical cluster formation in Kobe through advanced clinical research and other efforts and serves as the main organization supporting KBIC. Those who are interested in establishing entities in Japan, in investing or in finding partners either of academia, medical bodies or industries, please contact us.
201 to 500 staff
Stemcell Institute Inc
STEMCELL INSTITUTE INC. is a company based out of Tokyo, Japan.
51 to 200 staff
Agrevo International
Export Japan's advanced technology abroad. · International sales of Japanese agricultural technology.
501 to 1000 staff
Cellfree Sciences Co., Ltd
It is our goal to make proteins work! CellFree Sciences is a Japanese company using its own wheat germ cell-free protein expression system to serve protein needs in life sciences and industrial R&D projects. Performing protein synthesis outside a cell in an in vitro system allows us to separate protein production from other processes required to maintain a cell. Working cell-free opens new opportunities to better adopt protein synthesis to protein needs offering dedicated conditions to make for example membrane proteins, labeled proteins for NMR, or well-folded antigens for antibody production. Our scalable and flexible expression system can serve protein needs from the small amounts used for production of our protein bead arrays presenting human full-length proteins to individual proteins made on large-scale for use in structural biology, medical research, and diagnostic tests. Our plant-based expression system has a strong record on supporting a wide range of projects working on all kinds of proteins from the kingdoms of life. Talk to us for protein expression reagents and services that meet with your requirements.
11 to 50 staff
Chordia Therapeutics Inc
Chordia Therapeutics is a clinical-stage biotech company engaged in the research and development of novel therapies for cancers with high unmet medical needs. The Company was spun out from Takeda Pharmaceutical in November 2017.
11 to 50 staff
Glytech, Inc
GlyTech is a science-driven biotechnology company focusing on bringing glycans, which have been called the third chain of life, into practical therapeutic use. Our unparalleled platform technologies of human-type glycan production and glycosylation allow access to highly pure and structurally controlled glycans for drug modification. Our ability to precisely attach desired glycans to a broad range of drug types allows us to support our partners in a wide variety of drug development areas from basic research to manufacturing. A high level of control enables glycosylation patterns (structure, number, position) to be optimized to exploit potential benefits which include increased biological activity, prolonged half-life, and enhanced solubility. Our methods can help our partners advance discovery targets toward the clinic and develop new biotherapeutics more efficiently. We’ve also overcome one of the greatest barriers to the use of glycans in medicines: limited production capabilities. Our unique platforms allow us to produce both single glycan structures and uniformly glycosylated compounds on a practical and cost-effective scale from the research laboratory to commercialization. We are committed to helping our partners expand their glycoscience research fields, drug development options, and biotherapeutic analysis capabilities. We believe that technology, partnership, and passion are the 3 key success factors in the healthcare industry. With strong experience and an eagerness to tackle new challenges, we are ready to help our partners explore the possibilities of applied glycoscience. We invite you to get our updates by following us on Twitter or here on LinkedIn, or contact us through our homepage:
11 to 50 staff
Myoridge
We are specialists of culture media and cells with both manufacturing and contract research functions. Service lineup Providing custom culture media for cell therapy and immunotherapy Development of culture media that amplify or control specific functions of cells Development and supply of culture media that meet individual needs such as growth ability, cost reduction, and storage Development of iPS cells for specific disease models Support for development of differentiation induction technology for various cells.and more.
11 to 50 staff
Peptidream Inc
Our vision and mission at PeptiDream is to revolutionize drug discovery by discovering the next generation of transformational therapeutics and diagnostics that will lead to a healthier tomorrow for patients worldwide. With our proprietary PDPS (Peptide Discovery Platform System) technology, one of the world’s most advanced drug discovery platforms, at our core, we have grown from a small university startup into one of the largest biotech companies in Japan, with a global reputation as the leading peptide discovery company. Along the way we have greatly expanded our R&D capabilities, made and continue to witness exceptional technological breakthroughs, while expanding the uses of peptides across a growing variety of modalities, such as peptide-drug conjugates (PDCs) and multi-functional peptide conjugates (MPCs), and allowing us to create an ever-growing pipeline of innovative therapeutic and diagnostic programs, which we continue to partner out to a wide range of companies for clinical development and commercialization. The integration of PDRadiopharma represents a further extension of these efforts, positioning us to transform the field of targeted-radiopharmaceuticals.
501 to 1000 staff
Pfi Research And Development
Pharma Foods International Co Ltd is a global company based out of Japan.
201 to 500 staff
Theta Therapeutics, Inc
Theta Therapeutics is a biotech startup originating from university research. We specialize in formulation development for macrocyclic drug candidates aimed at treating rare and intractable diseases. Macrocyclic compounds represent a new class of therapeutics with unique cyclic structures, different from small molecules, nucleic acids, or antibodies. Although they hold great potential in areas such as oncology, their development is often hindered by issues like low solubility, toxicity, and inefficient delivery. Our mission is to address these barriers by creating innovative formulations that preserve therapeutic activity while enhancing solubility, safety, and tolerability.
1 to 10 staff
